Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter studyMaël Heiblig, Pierre Sujobert, Marcela A. Ferrada et al.|Blood|2022Cited by 212
A matched case–control study of toxoplasmosis after allogeneic haematopoietic stem cell transplantation: still a devastating complicationAnne Conrad, Guillaume Monneret, Fiorenza Barraco et al.|Clinical Microbiology and Infection|2016Cited by 45
Torque Teno Virus Viral Load as a Marker of Immune Function in Allogeneic Haematopoietic Stem Cell Transplantation RecipientsWilliam Mouton, Anne Conrad, Antonin Bal et al.|Viruses|2020Cited by 40
Class I/Class II HLA Evolutionary Divergence Ratio Is an Independent Marker Associated With Disease-Free and Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid LeukemiaAnne-Marie Daull, Vincent Alcazer, Valérie Dubois et al.|Frontiers in Immunology|2022Cited by 25
Clinical Efficacy of JAK Inhibitors in Patients with Vexas Syndrome: A Multicenter Retrospective StudyMaël Heiblig, Pierre Sujobert, Marcela A. Ferrada et al.|Blood|2021Cited by 12